WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new data from its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking ...

Bayer's blockbuster hopes for Nubeqa just got a little brighter, thanks to a phase 3 trial win that could result in the drug reaching more patients. A combination of Bayer’s androgen receptor ...

Consistent benefits in radiological progression-free survival were observed across patient subgroups. An analysis of immature data of overall survival suggested potential benefit with darolutamide ...

Add Yahoo as a preferred source to see more of our stories on Google. Logo of German drugmaker Bayer AG in Leverkusen FRANKFURT (Reuters) - Bayer on Thursday predicted at least $1 billion in 2024 ...

The survey also showed that many Americans lacked knowledge on prostate and breast cancers, two of the most common forms of the disease. (Photo by: HUMBERT/BSIP/Education Images/Universal Images Group ...

FRANKFURT (Reuters) -A therapy mix including Bayer's Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer in a clinical study, prompting the ...

Bayer requested a preliminary injunction over J&J’s Erleada marketing, arguing its headline survival claims rely on flawed real-world data, not clinical trials. The judge ruled that Bayer failed to ...

LOS ANGELES, Dec. 5, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Bayer today announced three 2023 Bayer-PCF Health Equity Research Challenge Awards totaling $600,000. The awards will ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) as well as the submission of a ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...